[go: up one dir, main page]

MX2015008538A - Composicion que comprende un extracto purificado que se aisla de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir o tratar enfermedad pulmonar obstructiva cronica y su uso. - Google Patents

Composicion que comprende un extracto purificado que se aisla de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir o tratar enfermedad pulmonar obstructiva cronica y su uso.

Info

Publication number
MX2015008538A
MX2015008538A MX2015008538A MX2015008538A MX2015008538A MX 2015008538 A MX2015008538 A MX 2015008538A MX 2015008538 A MX2015008538 A MX 2015008538A MX 2015008538 A MX2015008538 A MX 2015008538A MX 2015008538 A MX2015008538 A MX 2015008538A
Authority
MX
Mexico
Prior art keywords
active ingredient
isolated
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
MX2015008538A
Other languages
English (en)
Other versions
MX374074B (es
Inventor
Yongnam Lee
Hyeongkyu Lee
Ji-Seok Yoo
Dae-Hee Shin
Byung-Hwan Ryoo
Ok-Kyoung Kwon
Doo-Young Kim
Hyuk-Hwan Song
Kyung Seop Ahn
Sei Ryang Oh
Shin In Sik
Seung Hyung Kim
Lee Suui
Original Assignee
Yungjin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yungjin Pharmaceutical Co Ltd filed Critical Yungjin Pharmaceutical Co Ltd
Publication of MX2015008538A publication Critical patent/MX2015008538A/es
Publication of MX374074B publication Critical patent/MX374074B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición que comprende un extracto purificado que se aísla a partir de Pseudolysimachion rotundum var. subintegrum que contiene una abundante cantidad de ingrediente activo o los compuestos que se aislan de este como un ingrediente activo para prevenir o tratar una enfermedad pulmonar obstructiva crónica y el uso de los mismos. Los compuestos y el extracto purificado de la invención mostraron una actividad anti-COPD potente sin respuesta agonista del receptor beta-2 a través de diversas pruebas in vivo así como también pruebas in vitro. Por lo tanto, se pueden utilizar como el alimento para la salud o terapéutica para el tratamiento y prevención de la enfermedad pulmonar obstructiva crónica (COPD).
MX2015008538A 2013-04-10 2014-04-09 Composicion que comprende un extracto purificado que se aisla de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir o tratar enfermedad pulmonar obstructiva cronica y su uso. MX374074B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130039458 2013-04-10
KR1020140036245A KR101476095B1 (ko) 2013-04-10 2014-03-27 고함량의 카탈폴 유도체를 다량 함유한 산꼬리풀 유래 꼬리풀 신규 정제물 또는 이로부터 분리된 카탈폴 유도체를 유효성분으로 포함하는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물
PCT/KR2014/003080 WO2014168413A1 (en) 2013-04-10 2014-04-09 The composition comprising a purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom, as an active ingredient for preventing or treating chronic obstructive pulmonary disease and the use thereof

Publications (2)

Publication Number Publication Date
MX2015008538A true MX2015008538A (es) 2016-04-15
MX374074B MX374074B (es) 2025-03-05

Family

ID=51993687

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008538A MX374074B (es) 2013-04-10 2014-04-09 Composicion que comprende un extracto purificado que se aisla de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir o tratar enfermedad pulmonar obstructiva cronica y su uso.
MX2018015217A MX386593B (es) 2013-04-10 2014-04-09 Composicion que comprende un verprosido como ingrediente activo para prevenir o tratar una enfermedad pulmonar obstructiva cronica y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018015217A MX386593B (es) 2013-04-10 2014-04-09 Composicion que comprende un verprosido como ingrediente activo para prevenir o tratar una enfermedad pulmonar obstructiva cronica y su uso

Country Status (14)

Country Link
US (2) US9655871B2 (es)
EP (2) EP3586859A1 (es)
JP (1) JP5982077B2 (es)
KR (1) KR101476095B1 (es)
CN (1) CN105120880B (es)
AU (1) AU2014251492B2 (es)
BR (1) BR112015025595A2 (es)
CA (2) CA2905356C (es)
EC (1) ECSP15025868A (es)
ES (1) ES2728548T3 (es)
MX (2) MX374074B (es)
PL (1) PL3019182T3 (es)
RU (1) RU2594061C1 (es)
WO (1) WO2014168413A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476095B1 (ko) 2013-04-10 2014-12-23 영진약품공업주식회사 고함량의 카탈폴 유도체를 다량 함유한 산꼬리풀 유래 꼬리풀 신규 정제물 또는 이로부터 분리된 카탈폴 유도체를 유효성분으로 포함하는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물
EP4326280B1 (en) * 2021-04-24 2025-11-12 Goldlake Lifesciences Pvt Ltd Pharmaceutical compositions comprising picroside
CN115554286A (zh) * 2022-11-17 2023-01-03 云南养瑞科技集团有限公司 咖啡酸衍生物在制备治疗慢性阻塞性肺病药物中的应用
KR102849917B1 (ko) * 2022-12-30 2025-08-25 대구한의대학교산학협력단 베프로시드를 함유하는 골관절염 개선용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100349590C (zh) * 2004-07-02 2007-11-21 罗何生 地黄茎叶及其提取物抗哮喘和抗过敏的医药用途
KR100860080B1 (ko) 2005-05-30 2008-09-24 한국생명공학연구원 항염, 항알레르기 및 항천식 활성을 갖는 꼬리풀속 식물추출물을 함유하는 약학조성물
CA2610211C (en) * 2005-05-30 2012-02-21 Hyeong Kyu Lee Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity
KR20060125499A (ko) 2005-05-30 2006-12-06 한국생명공학연구원 항염, 항알레르기 및 항천식 활성을 갖는 긴산꼬리풀추출물로부터 분리된 카탈폴 유도체를 함유하는 약학조성물
KR101476045B1 (ko) * 2012-12-31 2014-12-23 영진약품공업주식회사 활성성분을 다량 함유한 산꼬리풀 정제 분획물 (atc2), 이의 제조방법 및 이를 유효성분으로 포함하는 염증, 알레르기 및 천식의 예방 또는 치료용 조성물
KR101476095B1 (ko) 2013-04-10 2014-12-23 영진약품공업주식회사 고함량의 카탈폴 유도체를 다량 함유한 산꼬리풀 유래 꼬리풀 신규 정제물 또는 이로부터 분리된 카탈폴 유도체를 유효성분으로 포함하는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
KR20140122656A (ko) 2014-10-20
MX374074B (es) 2025-03-05
EP3019182B1 (en) 2019-03-13
AU2014251492A1 (en) 2015-11-12
AU2014251492B2 (en) 2018-12-06
US9655871B2 (en) 2017-05-23
MX386593B (es) 2025-03-19
CA2905356C (en) 2018-05-22
PL3019182T3 (pl) 2019-09-30
BR112015025595A2 (pt) 2017-07-18
EP3019182A1 (en) 2016-05-18
CN105120880A (zh) 2015-12-02
US10172816B2 (en) 2019-01-08
US20170266142A1 (en) 2017-09-21
CN105120880B (zh) 2017-06-13
KR101476095B1 (ko) 2014-12-23
JP5982077B2 (ja) 2016-08-31
ECSP15025868A (es) 2016-01-29
RU2594061C1 (ru) 2016-08-10
EP3019182A4 (en) 2016-09-28
WO2014168413A1 (en) 2014-10-16
CA2905356A1 (en) 2014-10-16
JP2016516783A (ja) 2016-06-09
EP3586859A1 (en) 2020-01-01
CA2957180C (en) 2019-10-15
ES2728548T3 (es) 2019-10-25
CA2957180A1 (en) 2014-10-16
US20160051612A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CR20150326A (es) Inhibidores de autotaxina
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
MX2014012742A (es) Composicion para el tratamiento de transtornos metabólicos.
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2016000007A (es) Pirazolpiridinas sustituidas

Legal Events

Date Code Title Description
FG Grant or registration